Twitter Facebook Linked In Zone In Google Plus 
May 2018 Research Update

Super GMOs with a Super CRISPR/Cas9

Last month in The CRISPR Journal researchers from Kansas State University demonstrated that improved wheat varieties can be generated using a multiplexed CRISPR-Cas9-based system.

Wheat is the leading grain produced worldwide based on acreage. As world population continues to expand and the environmental landscape becomes increasingly unpredictable, improving agronomic traits of this vital crop becomes increasingly important.

Astonishingly, despite the rise of genetically modified crops, there are still no commercial strains of genetically modified wheat. This is due to the difficulty in controlling heritability in the offspring plants. Wheat is allopolyploid (it inherits chromosomes from three parent plants) and it is estimated that traditional breeding strategies take as many as 7-10 years before target genes are fully integrated.

Multiplexed gene editing (MGE) strategies simultaneously edit multiple genes by introducing multiple gRNAs. Although they have previously been used in a variety of species, including wheat, MGE strategies have had limitations. With wheat, for example, researchers placed each gRNA under its own promoter in a single construct. However, due to the size of the individual promoter-gRNA units, the level of multiplexing was limited...

Read More
 
Not enough RNA for your small RNA library prep?
CleanTag™ technology enables ultra-low single cell level RNA inputs. This kit blocks adapter dimer formation and eliminates the need for gel purification, facilitating full library prep automation. CleanTag is compatible with Illumina and Thermo NGS Platforms.
Come and See Us
TIDES Oligonucleotide & Peptide Therapeutics
May 7-10 Boston, MA
Booth #334
Schedule a meeting
OligoBuilder
Get instant pricing & ordering for modified and standard oligos from 0.2 µmole to 15 µmole synthesis scales.
We Bring the Best in Nucleic Acid Expertise to TIDES Every Year

Join us at our workshops,
schedule a meeting with our thought leaders,
or visit us at booth #334.

Monday May 7, 2018 | 9:00-10:00

  • Design and Manufacturing of Chemically Modified Messenger RNA Therapeutics - Anton McCaffrey PhD., Senior Director of Research and Development, TriLink BioTechnologies

Tuesday May 8, 2018 | 11:45-12:55

  • Overview - Mike Houston PhD., Chief Scientific Officer, TriLink BioTechnologies
  • Quantifying How Thousands of Nanoparticles Deliver Nucleic Acids In Vivo Using DNA Barcodes - James Dahlman PhD., Georgia Tech, Emory School of Medicine
  • Taking CRISPR to the Clinic - TJ Cradick PhD., Head of Genome Editing, CRISPR Tx
 
Tides
 
Ask An Expert

We need to quickly move forward with our novel therapeutic oligo. Can TriLink produce clinical grade material and quantities?

Yes! For over 20 years, we've been industry leaders synthesizing high quality research and diagnostic grade material, especially difficult and unusual constructs. We combine our expertise with a state-of-the art GMP manufacturing facility to offer mRNA, oligonucleotide and small molecule therapeutic development and...

Read More
Zone In With The Zon Blog Post

DNA Origami - Self-Assembling DNA Nanostructures

• Ned Seeman's Beer-Assisted "Epiphany" for DNA Self-Assembly Has Led to DNA Nanotechnology

• Creating DNA Origami Is the DNA-Equivalent of the Japanese Art of Paper Folding

• You'll Be Amazed at What Can Now Be Made from DNA Origami

View Blog Post


 

 
 
© 2018 TriLink BioTechnologies | All Rights Reserved